Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
about
Pioglitazone for type 2 diabetes mellitusPharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes.Patient factors associated with hemoglobin A1C change with pioglitazone as adjunctive therapy in type 2 Diabetes Mellitus.Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.Pioglitazone and metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapyAchieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.Risk management in the treatment of type 2 diabetes with pioglitazoneEvaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.Observational and clinical trial findings on the comparative effectiveness of diabetes drugs showed agreement.Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis.Rosiglitazone RECORD study: glucose control outcomes at 18 months.Pioglitazone and sulfonylureas: effectively treating type 2 diabetesAssociation of APOE polymorphisms with diabetes and cardiometabolic risk factors and the role of APOE genotypes in response to anti-diabetic therapy: results from the AIDHS/SDS on a South Asian population.A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesTreatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes.PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.Metformin: an old but still the best treatment for type 2 diabetes.Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin.The effects of pioglitazone on biochemical markers of bone turnover in the patients with type 2 diabetes.Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with MetforminBanting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitusThiazolidinedione derivatives in diabetes and cardiovascular disease: an update.Redefining the role of thiazolidinediones in the management of type 2 diabetesEffect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes.Metformin therapy and clinical uses.Self-monitoring of blood glucose in diabetes mellitus: arguments for an individualized approach.Addition of sulphonylurea to metformin does not relevantly change body weight: a prospective observational cohort study (ZODIAC-39).Diabetes medications and body weight.Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes.Add-on therapies to metformin for type 2 diabetes.Review of approved pioglitazone combinations for type 2 diabetes.Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.Comparative evaluation of incretin-based antidiabetic medications and alternative therapies to be added to metformin in the case of monotherapy failure.
P2860
Q24244321-929630C3-B597-44A7-A527-950E4634B9B7Q30249371-BBAA4CB3-8D84-47A2-B78C-0DEC833336F6Q30438098-161C0426-91AE-45A7-ABF6-DEA2961747E1Q34078900-C8BED4A3-E1F7-4FAC-BECC-17F4A3F0BF7EQ34110707-F99B084D-7807-4D0E-BF17-B64F2A23157FQ34139048-8095FEC8-C2F2-4086-8B06-265F116DB3DEQ34324440-528FA04D-CFD1-4216-A6AD-85CAB87828F1Q34449858-4881FC3F-E539-4715-901D-5AE25EB8E282Q34563587-912ACE10-4E30-4690-8B7F-A1ABE9A5F944Q34592900-AEEF9766-CB40-49B6-8985-AEB1B712E83AQ34620706-15847ADE-F201-4DC6-BCB1-159A15A040DAQ35138216-60A4CDD8-46C7-44C8-906D-2EB6B43A3A5BQ35146648-382FB73D-512D-4484-8C36-C43A31D57144Q35496591-D7991765-6531-4B9C-81E1-D20EEA460531Q35949722-9F2D6132-85D6-414A-A77C-B4F292DA43B4Q35987411-994CEC43-E1CB-49CB-91ED-3ADED7338EEFQ35987456-4C040C9E-BF80-44A2-BD7C-2ADA6B82EFF2Q36307711-22DB6F71-65DE-462B-B3E9-FC3A8A7D7B6DQ36536205-1CF99956-D9A6-48F3-9CA8-F1CFE945EBCDQ36536290-A229EC0C-ABF1-472B-A173-40184A19B698Q36536316-3C3FCCF5-0B0A-4621-8A2F-6D04F6FEC714Q36715464-F43A4F95-816A-4725-99E2-F4E989DFD889Q36812821-6A8F4E3E-DD48-4E63-A704-061CAC16CDB9Q36969616-0519AAA8-80B1-44F6-A83E-70014D7D0254Q37056847-D73B4C08-2D30-4FA5-8580-AC1192B853C5Q37141727-2F8FB46E-7BCB-4C58-A796-2C8317748C55Q37142138-2321AE32-9BBC-436E-B73F-724AB71100D2Q37167551-A84F82E9-CE49-4F65-A46E-0E838C8D4C8EQ37207116-F89267FC-853B-4420-A976-6DB9647F0A79Q37262966-C183D3BF-7A2B-4EE9-86B2-16DC8D14BE9FQ37405143-17073389-3BB8-44C3-965B-A20424986FA1Q37456636-C3468A86-100C-4F97-9216-E9AA82AFFA43Q37524006-F273710D-73C8-4B9C-9B22-D1781FD8E790Q37577159-19BFAC00-6BB1-48B6-BC9C-7053B7D9BB93Q37577162-4F087284-1B01-4406-85E0-35B12BF7E648Q37818234-D11DE2B7-1A1C-4B14-A364-95E23E18B605Q37884618-6DCD7F8B-9705-495C-AD6A-3CFFDE717E3EQ38092275-3A40DA86-7D14-410D-9B06-66B066EC3816Q38163071-28C94A44-60B9-4923-A4EB-AFAB725275E8Q38213037-6CC4DBEC-9A28-498E-96C7-8123084BC2F7
P2860
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@en
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@nl
type
label
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@en
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@nl
prefLabel
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@en
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@nl
P2093
P921
P1433
P1476
Long-term efficacy and tolerab ...... patients with type 2 diabetes.
@en
P2093
B Charbonnel
D R Matthews
G Schernthaner
P Brunetti
R Urquhart
P2888
P304
P356
10.1007/S00125-005-1751-1
P577
2005-05-12T00:00:00Z